Pair page
Livagen with NAD+
Mechanism-tag overlap and published literature for Livagen and NAD+, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
khavinson-lymphoid-hepatic-bioregulator
coenzymemitochondrial-longevity
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Livagen and NAD+ have published these mechanism-level observations. Not a co-administration recommendation.
Supports hepatic sirtuin and mitochondrial metabolism. Mechanism-complementary to the proposed gene-expression reset of Livagen, particularly in the hepatic longevity context.
Quick facts
Livagen
NAD+
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2021 | Livagen | Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID: 34834147. (Recent programmatic review of Khavinson peptide-DNA interaction framework.) PMID 34834147 | systematic review |
| 2011 | Livagen | Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). 2011;76(11):1210-1219. PMID:… PMID 22117546 | preclinical, in vitro |
| 2015 | Livagen | Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Moscow). 2015;80(3):310-322. PMID: 25761685. PMID 25761685 | mechanism / discovery |
| 2007 | Livagen | Khavinson VKh. Tetrapeptide KEDA decondenses heterochromatin in hepatocyte nuclei and modulates liver gene expression. (Khavinson-group experimental work across Russian-language publications, 2007–2012, Bulletin of Experimental Biology and Medicine.) | mechanism / discovery |
| 2003 | Livagen | Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937682. (Telomerase claim framework.) PMID 12937682 | mechanism / discovery |
| 2003 | Livagen | Khavinson VKh, Malinin VV, Myl'nikov SV. Effect of peptides on lifespan of animals and peptide-dependent gene expression. Bull Exp Biol Med. 2003;135(4):373-375. PMID: 12820081. PMID 12820081 | mechanism / discovery |
| 2021 | Livagen | Fedoreyeva LI, Vanyushin BF. Epigenetic Activity of Short Peptides and Their Interaction with Nucleic Acids. Biol Bull Rev. 2021;11:351-362. (Broader Khavinson-framework review of short-peptide chromatin interactions.) | review |
| 2002 | Livagen | Khavinson VK. Peptides and Ageing. Neuroendocrinol Lett. 2002;23 Suppl 3:11-144. PMID: 12374919. (Comprehensive review of the Khavinson short-peptide bioregulator framework, including KEDA / Livagen.) PMID 12374919 | review |
| 2010 | Livagen | Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19730006. PMID 19730006 | bioregulator literature |
| 2005 | Livagen | Khavinson VK, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger Publishers; 2005. ISBN 3-8055-7905-5. (Book-length monograph of the Khavinson framework.) | bioregulator literature |
| 2003 | Livagen | Khavinson VKh, Lezhava TA, Monaselidze JR, Jokhadze TA, Dvalishvili NA, Bablishvili NK, Trofimova SV. Peptide Epitalon activates chromatin at the old age. Neuroendocrinol Lett. 2003;24(5):329-333. PMID: 14647006. (Chromatin activation framework; Epithalon but same mechanistic fr… PMID 14647006 | bioregulator literature |
| 2003 | Livagen | Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuroendocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363. PMID 14523363 | bioregulator literature |
| 2015 | NAD+ | Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziell RA, McKenzie CA, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, St George G, Chinniah N, Halliday GM, Damian DL. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med. 2015;373(17):1618-1626… PMID 26488693 | human trial, Phase 3 |
| 2023 | NAD+ | Katayoshi T, Uehata S, Nakashima N, Nakajo T, Kitajima N, Kageyama M, Tsuji-Naito K. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Sci Rep. 20… PMID 36797283 | human trial |
| 2018 | NAD+ | Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, Stødkilde-Jørgensen H, Møller N, Brenner C, Treebak JT, Jessen N. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effect… PMID 30084900 | human trial |
| 2017 | NAD+ | Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, Tian R, Shen DD, O'Brien KD. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy voluntee… PMID 29211728 | human trial |
| 2022 | NAD+ | Brakedal B, Dölle C, Riemer F, Ma Y, Nido GS, Skeie GO, Craven AR, Schwarzlmüller T, Brekke N, Diab J, Sverkeli L, Skjeie V, Varhaug K, Tysnes OB, Peng S, Haugarvoll K, Ziegler M, Grüner R, Eidelberg D, Tzoulis C. The NADPARK study: A randomized phase I trial of nicotinamide rib… PMID 35537443 | human trial, Phase 1 |
| 2019 | NAD+ | Grant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, Watson J. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Front Aging Neurosci. 2019;11:257. PMID: 31572171. PMID 31572171 | human pilot |
| 2018 | NAD+ | Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. PMID: 29599478. PMID 29599478 | human study |
| 2023 | NAD+ | Vreones M, Mustapic M, Moaddel R, Pucha KA, Lovett J, Seals DR, Kapogiannis D, Martens CR. Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin. Aging Cell. 2023;22(1):e13754. PM… PMID 36448627 | research article |
| 2022 | NAD+ | Freeberg KA, Craighead DH, Martens CR, You Z, Chonchol M, Seals DR. Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Midlife and Older Adults. Front Cardiovasc Med. 2022;9:881703. PMID: 35757350. PMID 35757350 | research article |
| 2021 | NAD+ | Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PMID: 33888596. PMID 33888596 | research article |
| 2019 | NAD+ | Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, Cartwright DM, Oakey L, Burley CV, Jenkinson N, Wilson M, Lucas SJE, Akerman I, Seabright A, Lai YC, Tennant DA, Nightingale P, Wallis GA, Manolopoulos KN, Brenner C, Philp A, Lavery GG. Nicotinamide Riboside A… PMID 31390667 | research article |
| 2018 | NAD+ | Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018;27(3):513-528. PMID: 29249689. PMID 29249689 | research article |
Related pair pages
More research context
Frequently asked
Have Livagen and NAD+ been studied together?
Researchers have published mechanistic-level co-administration discussion of Livagen and NAD+. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Livagen and NAD+ share?
Livagen and NAD+ do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Livagen and NAD+?
Livagen: Not approved. NAD+: Not approved (IV off-label). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Livagen and NAD+?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Livagen profile and the NAD+ profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026